STOCKHOLM — Trial results are demonstrating the safety and effectiveness of a novel gene modifier therapy for treating retinitis pigmentosa associated with NR2E3 and RHO mutations. Researchers ...

According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...

Scientists have identified two non-retinoid compounds that may be able to treat retinitis pigmentosa (RP), a group of inherited eye diseases that cause blindness. The compounds were discovered by ...

Retinitis pigmentosa, a degenerative genetic disease of the eye, is characterized by progressive vision loss, usually leading to blindness. In some patients, structural defects in the photoreceptor ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

EA-2353 is a novel, small molecule designed to selectively activate endogenous retinal stem and progenitor cells. The Food and Drug Administration (FDA) has granted Fast Track designation to EA-2353 ...

Retinal degeneration in the disease retinitis pigmentosa is caused by a family of hereditary mutations that slowly lead to blindness over years or decades. A mouse model of one of these forms of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The investigational cell therapy is designed to replace ...

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health ®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), ...

Before you submit an error, please consult our Video Help page. Carolina Impact is available to stream on pbs.org and the free PBS App, available on iPhone, Apple TV, Android TV, Android smartphones, ...